Liang Ji
- Cancer Research top 10%
- Cancer-related molecular mechanisms research 2
-
- RNA modifications and cancer 3
- Toxicology top 10%
- Bioactive Compounds and Antitumor Agents 1
-
- Pancreatic and Hepatic Oncology Research 5
-
- Pancreatitis Pathology and Treatment 12
- Pediatric Hepatobiliary Diseases and Treatments 3
-
- Phagocytosis and Immune Regulation 2
-
- Acute Ischemic Stroke Management 2
- Co-authors
- Bei SunJ D MinnaB FangJack A. RothKwun M. FongNancy YenGang WangXuewei Bai
- Partner nations
- ChinaUnited States
In The Last Decade
Liang Ji
24 papers receiving 856 citations
Peers
Comparison fields: 5 of 79
- Cancer Research 235
- Molecular Biology 550
- Toxicology 27
- Oncology 183
- Genetics 157
Countries citing papers authored by Liang Ji
This map shows the geographic impact of Liang Ji's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Liang Ji with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Liang Ji more than expected).
Fields of papers citing papers by Liang Ji
This network shows the impact of papers produced by Liang Ji. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Liang Ji. The network helps show where Liang Ji may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Liang Ji, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2025 | 0 | |
| 3 | 2025 | 1 | |
| 4 | 2025 | 0 | |
| 5 | 2024 | 11 | |
| 6 | 2022 | 14 | |
| 7 | 2022 | 22 | |
| 8 | 2021 | 5 | |
| 9 | 2019 | 14 | |
| 10 | 2019 | 30 | |
| 11 | 2019 | 20 | |
| 12 | 2018 | 8 | |
| 13 | 2017 | 35 | |
| 14 | 2017 | 33 | |
| 15 | 2016 | 19 | |
| 16 | 2016 | 14 | |
| 17 | 2015 | 36 | |
| 18 | 2007 | 54 | |
| 19 | 2006 | 30 | |
| 20 | Induction of apoptosis and inhibition of tumorigenicity and tumor growth by adenovirus vector-mediated fragile histidine triad (FHIT) gene overexpression. | 1999 | 211 |
About Liang Ji
Liang Ji is a scholar working on Surgery, Toxicology and Oncology, having authored 26 papers that have together received 865 indexed citations. Recurring topics across this work include Pancreatitis Pathology and Treatment (12 papers), Pancreatic and Hepatic Oncology Research (5 papers), Pediatric Hepatobiliary Diseases and Treatments (3 papers), RNA modifications and cancer (3 papers), Phagocytosis and Immune Regulation (2 papers), Acute Ischemic Stroke Management (2 papers), Cancer-related molecular mechanisms research (2 papers) and Bioactive Compounds and Antitumor Agents (1 paper). The work is most often cited by research in Cancer Research (235 citations), Molecular Biology (550 citations) and Toxicology (27 citations). Liang Ji has collaborated with scholars based in China and United States. Frequent co-authors include Bei Sun, J D Minna, B Fang, Jack A. Roth, Kwun M. Fong, Nancy Yen, Gang Wang, Xuewei Bai, Guangquan Zhang and Hua Chen. Their work appears in journals such as Oncogene, Frontiers in Immunology and Biochemical Pharmacology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.